{
    "eid": "2-s2.0-85159079279",
    "title": "Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders",
    "cover-date": "2023-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Psychiatry and Mental Health",
            "@code": "2738",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Dicson S. Malar",
        "Premrutai Thitilertdecha",
        "Kanokphorn S. Ruckvongacheep",
        "Sirikalaya Brimson",
        "Tewin Tencomnao",
        "James M. Brimson"
    ],
    "citedby-count": 1,
    "ref-count": 442,
    "ref-list": [
        "Purification, molecular cloning, and expression of the mammalian sigma1-binding site",
        "\u03c3-1 Receptors (\u03c31 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export",
        "Regulating ankyrin dynamics: roles of sigma-1 receptors",
        "Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands",
        "Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression",
        "Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor",
        "Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria",
        "The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator",
        "Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders",
        "The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines",
        "Allosteric modulators of sigma-1 receptor: a review",
        "The sigma receptor: evolution of the concept in neuropsychopharmacology",
        "Classification and nomenclature of phencyclidine and sigma receptor sites",
        "Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo",
        "Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation",
        "Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival",
        "Rat liver and kidney contain high densities of \u03c31 and \u03c32 receptors: characterization by ligand binding and photoaffinity labeling",
        "\u03c3-Receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary",
        "An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer",
        "Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy",
        "Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma",
        "Sigma receptors [\u03c3Rs]: biology in normal and diseased states",
        "Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor",
        "The roles of intracellular chaperone proteins, sigma receptors, in Parkinson's disease (PD) and major depressive disorder (MDD)",
        "Sigma receptor (\u03c3R) ligands with antiproliferative and anticancer activity",
        "Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes",
        "Lipid rafts: elusive or illusive?",
        "Structures of the \u03c32 receptor enable docking for bioactive ligand discovery",
        "Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders",
        "Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations",
        "NO1, a new Sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines",
        "Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer",
        "The biological function of Sigma-2 receptor/TMEM97 and its utility in PET imaging studies in cancer",
        "2021 Alzheimer's disease facts and figures",
        "Alzheimer's disease",
        "Amyloid-dependent and amyloid-independent stages of Alzheimer disease",
        "Alzheimer's disease",
        "A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease",
        "Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation",
        "Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics",
        "Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction",
        "Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury",
        "Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice",
        "Sigma 1 receptor: a new therapeutic target for pain",
        "An increase of sigma1 receptors in the aged monkey brain",
        "Sigma binding sites identified by [3H] DTG are elevated in aged Fischer-344\u00d7 Brown Norway (F1) rats",
        "Age-related changes of the binding of [3H] SA4503 to sigma1 receptors in the rat brain",
        "Cardiac 11C-donepezil binding increases with age in healthy humans: potentially signifying Sigma-1 receptor upregulation",
        "In vivo imaging of muscarinic receptors in the aging female brain with (R, R)[123I]-I-QNB and single photon emission tomography",
        "Greater loss of 5-HT2A receptors in midlife than in late life",
        "Age-related reduction of extrastriatal dopamine D2 receptor measured by PET",
        "Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain",
        "The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer\u2019s Disease",
        "Low density of sigma 1 receptors in early Alzheimer\u2019s disease",
        "Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease",
        "A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease",
        "Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer\u2019s disease and mild cognitive impairment",
        "Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease",
        "Association between a variant of the sigma-1 receptor gene and Alzheimer's disease",
        "Roles of sigma-1 receptors in Alzheimer\u2019s disease",
        "Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1\u2022GTP pathway",
        "AF710B, a novel M1/\u03c31 agonist with therapeutic efficacy in animal models of Alzheimer's disease",
        "Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor",
        "Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid",
        "Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo",
        "Could autophagy dysregulation link neurotropic viruses to Alzheimer\u2019s disease?",
        "Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime",
        "Autophagy and Alzheimer\u2019s disease: from molecular mechanisms to therapeutic implications",
        "Dysregulated Ca2+ homeostasis as a central theme in neurodegeneration: lessons from Alzheimer\u2019s disease and Wolfram syndrome",
        "Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial",
        "Lecanemab in early Alzheimer\u2019s disease",
        "A\u03b2 oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease",
        "On the physiological/pathological link between A\u03b2 peptide, cholesterol, calcium ions and membrane deformation: a molecular dynamics study",
        "Alzheimer-type neuropathology in transgenic mice overexpressing V717F \u03b2-amyloid precursor protein",
        "The Pharmacology of the Sigma-1 Receptor",
        "Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia",
        "At the crossing of ER stress and MAMs: a key role of sigma-1 receptor?",
        "MAM: more than just a housekeeper",
        "ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology",
        "Developmental and epileptic encephalopathies: what we do and do not know",
        "Developmental and epileptic encephalopathies: recognition and approaches to care",
        "Deciphering the concepts behind \u201cEpileptic encephalopathy\u201d and \u201cDevelopmental and epileptic encephalopathy",
        "What are the epileptic encephalopathies?",
        "Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome",
        "New and emerging pharmacologic treatments for developmental and epileptic encephalopathies",
        "Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome",
        "Changing landscape of Dravet syndrome management: an overview",
        "An emerging role for Sigma-1 receptors in the treatment of developmental and epileptic encephalopathies",
        "Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures",
        "Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation",
        "Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease",
        "Energy deficit in Huntington disease: why it matters",
        "Treatment of Huntington\u2019s disease",
        "Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington\u2019s disease",
        "The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease",
        "Pridopidine in the treatment of Huntington\u2019s disease",
        "Role of sigma-1 receptors in neurodegenerative diseases",
        "The phenotypic variability of amyotrophic lateral sclerosis",
        "Longitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease",
        "Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians",
        "Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques",
        "A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group",
        "Sodium phenylbutyrate and ursodoxicoltaurine: first approval",
        "Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs",
        "Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial",
        "Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib",
        "Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: molecular compartmentation and response to peripheral nerve injury",
        "Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis",
        "Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N, N\u2032-dimethyltryptamine forming enzyme, indole-N-methyl transferase",
        "The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study",
        "Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1-and SOD 1-linked ALS",
        "Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis",
        "Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances",
        "The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins",
        "Lack of sigma-1 receptor exacerbates ALS progression in mice",
        "A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis",
        "The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis",
        "Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis",
        "Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis",
        "Stages of pTDP-43 pathology in amyotrophic lateral sclerosis",
        "Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models",
        "The relation between inflammation and neurodegeneration in multiple sclerosis brains",
        "Diagnosis and treatment of multiple sclerosis: a review",
        "Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease",
        "Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment",
        "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group",
        "Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes",
        "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis",
        "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study",
        "Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial",
        "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group",
        "Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis",
        "Immunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerve",
        "Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation",
        "Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases",
        "Local cholesterol metabolism orchestrates remyelination",
        "Neuronal mitochondrial dysfunction in a cellular model of circadian rhythm disruption is rescued by donepezil",
        "High-affinity \u03c31 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis",
        "Biomarkers for Parkinson\u2019s disease: recent advancement",
        "Finding useful biomarkers for Parkinson\u2019s disease",
        "Biomarkers for Parkinson\u2019s disease: how good are they?",
        "Parkinson\u2019s disease",
        "Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics",
        "Unmasking levodopa resistance in Parkinson\u2019s disease",
        "Lewy body dementias",
        "Risk of dementia in Parkinson\u2019s disease: a community-based, prospective study",
        "Function of sigma 1 receptors in Parkinson\u2019s disease",
        "Sigma-1 receptor knockout increases \u03b1-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra",
        "The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration",
        "Compromising \u03c3-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-\u03baB/Bcl-2-dependent mechanism: Potential relevance to Parkinson\u2019s disease",
        "Dopamine induces apoptosis in APPswe-expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments",
        "Dipentylammonium binds to the Sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines",
        "Parkinson disease",
        "Oxidative stress and the pathogenesis of Parkinson\u2019s disease",
        "NADPH oxidase 1 mediates \u03b1-synucleinopathy in Parkinson\u2019s disease",
        "Damage to dopaminergic neurons by oxidative stress in Parkinson\u2019s disease",
        "The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements",
        "Sigma 1 receptor regulates the oxidative stress response in primary retinal M\u00fcller glial cells via NRF2 signaling and system xc\u2212, the Na+-independent glutamate\u2013cystine exchanger",
        "The Sigma-1 receptors role in neuroprotection: Comment on Nrf2 as a therapeutic target in ischemic stroke",
        "Cleistocalyx nervosum var. paniala seed extracts exhibit sigma-1 antagonist sensitive neuroprotective effects in PC12 cells and protect C. elegans from stress via the SKN-1/NRF-2 pathway",
        "Bacopa monnieri protects neuronal cell line and Caenorhabditis elegans models of Alzheimer\u2019s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways",
        "Identification of synaptosomal proteins binding to monomeric and oligomeric \u03b1-synuclein",
        "Autophagy and human disease: emerging themes",
        "Wild type \u03b1-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells",
        "The role of lipids interacting with \u03b1-synuclein in the pathogenesis of Parkinson\u2019s disease",
        "Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of \u03b1-synuclein",
        "DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function",
        "Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson\u2019s patient brain-derived \u03b1-synuclein",
        "Rett syndrome: a genetic update and clinical review focusing on comorbidities",
        "Genetic landscape of Rett syndrome spectrum: improvements and challenges",
        "MeCP2, a key contributor to neurological disease, activates and represses transcription",
        "Rett syndrome: a complex disorder with simple roots",
        "Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome",
        "Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model",
        "MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively",
        "Evidence-based physical therapy for individuals with Rett syndrome: a systematic review",
        "Rett syndrome from bench to bedside: recent advances",
        "Rett Syndrome",
        "Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome",
        "Developmental delay in Rett syndrome: data from the natural history study",
        "Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice",
        "Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis",
        "Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2",
        "Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus",
        "Relationship between Sigma-1 receptor and BDNF in the visual system",
        "Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression",
        "Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells",
        "The sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy",
        "Wolfram syndrome: diagnosis, management, and treatment",
        "Current landscape of treatments for Wolfram syndrome",
        "Wolfram syndrome: MAMs\u2019 connection?",
        "Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival",
        "Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models",
        "Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study",
        "Amantadine inhibits NMDA receptors by accelerating channel closure during channel block",
        "Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine",
        "Amantadine: the journey from fighting flu to treating Parkinson disease",
        "Amantadine",
        "Amantadine in the treatment of Parkinson\u2019s disease",
        "Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders",
        "Affinity of 1-aminoadamantanes for the \u03c3 binding site in post-mortem human frontal cortex",
        "Amantadine for dyskinesia in Parkinson\u2019s disease",
        "Clinical pharmacokinetics of amantadine hydrochloride",
        "Amantadine extended release capsules (GOCOVRI) in Parkinson\u2019s disease: a profile of its use in the USA",
        "Effects of Gocovri (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson\u2019s disease and dyskinesia",
        "Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease",
        "Parkinson\u2019s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102",
        "Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3)",
        "ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial",
        "EASE LID 2: a 2-year open-label trial of gocovri (amantadine) extended release for dyskinesia in Parkinson\u2019s disease",
        "Amantadine, fatigue, and multiple sclerosis",
        "Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study",
        "Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis\u2013result of a pilot randomized, blind study",
        "Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis",
        "Effect of L-dopa or amantadine therapy on sleep spindles in Parkinsonism",
        "Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial",
        "Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative",
        "Blockade of Tau hyperphosphorylation and A\u03b2 1\u201342 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and \u03c3 1 receptor agonist, in a nontransgenic mouse model of Alzheimer\u2019s disease",
        "Mitochondrial protection by the mixed muscarinic/\u03c31 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A\u03b225\u201335 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model",
        "A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study",
        "Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis",
        "ANAVEX 2\u201373 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome",
        "Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy",
        "AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer\u2019s disease",
        "Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for Alzheimer\u2019s disease",
        "Alzheimer's therapeutics targeting amyloid beta 1\u201342 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity",
        "Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification",
        "Protective alleles and modifier variants in human health and disease",
        "A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease",
        "[P4\u2013567]: a phase 1 safety trial of the A\u03b2 oligomer receptor antagonist CT1812",
        "Dextromethorphan-induced serotonin syndrome",
        "Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats",
        "Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders",
        "Recognizing and treating pseudobulbar affect",
        "Dextromethorphan/quinidine",
        "Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial",
        "Agitation in Alzheimer\u2019s disease is a manifestation of frontal lobe dysfunction",
        "Efficacy and safety of AXS\u201005, a novel, oral, NMDA\u2010receptor antagonist with multimodal activity, in agitation associated with Alzheimer\u2019s disease: results from ADVANCE\u20101, a phase 2/3, double\u2010blind, active and placebo\u2010controlled trial: developments in clinical trials and cognitive assessment",
        "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan",
        "Dextromethorphan improves levodopa-induced dyskinesias in Parkinson\u2019s disease",
        "Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson\u2019s disease",
        "Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias",
        "The effect of dextromethorphan use in Parkinson\u2019s disease: a 6-hydroxydopamine rat model and population-based study",
        "Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson\u2019s disease",
        "A trial of dextromethorphan in parkinsonian patients with motor response complications",
        "Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy body dementia",
        "Dextromethorphan abuse leading to assault, suicide, or homicide",
        "Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial",
        "Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis",
        "Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis",
        "Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord",
        "Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules",
        "Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect",
        "Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis",
        "Chronic pain in persons with multiple sclerosis",
        "Sigma-1 receptor and pain",
        "Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis",
        "High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia",
        "Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients",
        "Analgesic effect of dextromethorphan in neuropathic pain",
        "A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias",
        "Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design",
        "Randomized open-label trial of dextromethorphan in Rett syndrome",
        "(2R-trans)-2-butyl-5-heptylpyrrolidine as a potent sigma receptor ligand produced by Streptomyces longispororuber",
        "High affinity of sigma1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8\u2013C7 isomerase",
        "The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids",
        "Sphingoid bases regulate the Sigma-1 receptor\u2014sphingosine and N,N\u2019-dimethylsphingosine are endogenous agonists",
        "TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons",
        "Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11 C-SA4503 and microPET",
        "The effect of donepezil treatment on cardiovascular mortality",
        "The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease",
        "Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection",
        "Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors",
        "Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis",
        "Donepezil for dementia due to Alzheimer\u2019s disease",
        "Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer\u2019s disease: a systematic review and meta-analysis",
        "Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease",
        "A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting",
        "Donepezil attenuates A\u03b2-associated mitochondrial dysfunction and reduces mitochondrial A\u03b2 accumulation in vivo and in vitro",
        "Effects of donepezil on amyloid-\u03b2 and synapse density in the Tg2576 mouse model of Alzheimer\u2019s disease",
        "Changes in brain amyloid-\u03b2 accumulation after donepezil administration",
        "Donepezil for the treatment of agitation in Alzheimer\u2019s disease",
        "Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?",
        "Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study",
        "Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of \u03c3 receptors",
        "Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson\u2019s disease?",
        "Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?",
        "Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon",
        "Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons",
        "Afobazole modulates microglial function via activation of both \u03c3-1 and \u03c3-2 receptors",
        "Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-\u03b225\u201335",
        "Afobazole activation of \u03c3-1 receptors modulates neuronal responses to amyloid-\u03b225\u201335",
        "Fenfluramine acts as a positive modulator of sigma-1 receptors",
        "Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders",
        "Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial",
        "Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial",
        "Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study",
        "Repurposing fluoxetine to treat lymphocytic leukaemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction",
        "Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study",
        "Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug ?",
        "Are fluoxetine\u2019s effects due to sigma-1 receptor agonism?",
        "Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study",
        "Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury",
        "Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging",
        "Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial",
        "Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis",
        "Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT",
        "Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial",
        "Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the Sigma-1 receptor and autophagy",
        "Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways",
        "Fluvoxamine treatment of major depression associated with multiple sclerosis",
        "Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis",
        "Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo",
        "Ketamine prevents stress-induced cognitive inflexibility in rats",
        "Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide",
        "Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: a phase IV multicentre randomised placebo-controlled double-blind clinical trial",
        "Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression",
        "Controversies of the effect of ketamine on cognition",
        "Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis",
        "Ketamine for depression: Where do we go from here?",
        "Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer\u2019s disease",
        "Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: a systematic review and network meta-analysis",
        "Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine",
        "Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson\u2019s disease",
        "Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson\u2019s disease",
        "Neuron-protective effect of subanesthestic-dosage ketamine on mice of Parkinson\u2019s disease",
        "The utility of ketamine for the preoperative management of a patient with Parkinson\u2019s disease",
        "A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson\u2019s disease: two case reports",
        "Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study",
        "Ketamine for treatment-resistant unipolar depression",
        "Breaking sad: unleashing the breakthrough potential of k etamine\u2019s rapid antidepressant effects",
        "Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression",
        "(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice",
        "(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut\u2013microbiota\u2013brain axis",
        "Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine",
        "Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: a case report",
        "Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype",
        "Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment",
        "Use of ketamine during procedural sedation: indications, controversies, and side effects",
        "Alzheimer disease: progress or profit?",
        "Memantine, donepezil, or combination therapy\u2014what is the best therapy for Alzheimer\u2019s disease? A network meta-analysis",
        "On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease",
        "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data",
        "The neuropharmacological basis for the use of memantine in the treatment of Alzheimer\u2019s disease",
        "The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus",
        "Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites",
        "Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors",
        "NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus",
        "Mechanism of action of ketamine",
        "Memantine in moderate to severe Alzheimer\u2019s disease: a meta-analysis of randomised clinical trials",
        "Memantine in patients with Alzheimer\u2019s disease receiving donepezil: new analyses of efficacy and safety for combination therapy",
        "Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis",
        "Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease",
        "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial",
        "Post Hoc Evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD Study and Memantine Clinical Trial Program",
        "Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial",
        "Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease",
        "Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial",
        "Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial",
        "Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study",
        "Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis",
        "Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study",
        "Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial",
        "Sodium diphenyl hydantoinate in the treatment of convulsive disorders",
        "The neurobiology of antiepileptic drugs",
        "Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction",
        "Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells",
        "Sigma-1 receptor plays a negative modulation on N-type calcium channel",
        "Sigma receptors inhibit high-voltage\u2013activated calcium channels in rat sympathetic and parasympathetic neurons",
        "Allosteric modulation of ligand binding to [3H](+) pentazocine-defined \u03c3 recognition sites by phenytoin",
        "Phenytoin as a last-resort treatment in SCN 8A encephalopathy",
        "Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy",
        "Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand",
        "PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation",
        "Sigma-1 receptor activation-induced glycolytic ATP production and endothelial barrier enhancement",
        "Activation of the sigma-1 receptor attenuates blood\u2013brain barrier disruption by inhibiting amyloid deposition in Alzheimer\u2019s disease mice",
        "Sigma receptor agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury",
        "Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism",
        "Hippocampus and its involvement in Alzheimer\u2019s disease: a review",
        "Neurogenesis in the adult human hippocampus",
        "Impact of two neuronal Sigma-1 receptor modulators, PRE084 and DMT, on neurogenesis and neuroinflammation in an A\u03b21\u201342-injected, wild-type mouse model of AD",
        "DHEA prevents A\u03b225\u201335-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling",
        "Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer\u2019s disease APP/PS1 mouse model",
        "Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons",
        "Sigma-1R agonist improves motor function and motoneuron survival in ALS mice",
        "Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?",
        "Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1G93A ALS mice",
        "Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation",
        "Sigma 1 receptor co-localizes with NRF2 in retinal photoreceptor cells",
        "Loss of Sigma-1 receptor chaperone promotes astrocytosis and enhances the Nrf2 antioxidant defense",
        "Sigma-1 receptor agonist PRE-084 confers protection against TAR DNA-binding protein-43 toxicity through NRF2 signalling",
        "Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-\u03baB pathway",
        "Neuroprotective effect of \u03c31-receptors on the cell model of Huntington\u2019s disease",
        "Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques",
        "Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study",
        "Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses",
        "Do thin spines learn to be mushroom spines that remember?",
        "Balancing structure and function at hippocampal dendritic spines",
        "Labelling and optical erasure of synaptic memory traces in the motor cortex",
        "Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model",
        "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis",
        "Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine",
        "Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice",
        "Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington\u2019s disease",
        "Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse",
        "BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice",
        "Pridopidine activates neuroprotective pathways impaired in Huntington disease",
        "Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release",
        "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease",
        "Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial",
        "Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study",
        "Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease",
        "The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model",
        "Clinical trial highlights \u2013 dyskinesia",
        "Priming for l-dopa-induced dyskinesia in Parkinson\u2019s disease: a feature inherent to the treatment or the disease?",
        "An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine",
        "Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors",
        "A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease",
        "Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial",
        "Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease",
        "Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer\u2019s disease",
        "Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA",
        "Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-\u03b2 peptide (1\u201340) in rats",
        "T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloid-\u03b2 peptide",
        "Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial",
        "The neuroprotective and neurotrophic agent T-817MA for Alzheimer\u2019s disease: randomized, double-blind, placebo-controlled proof-of-concept trial outcomes",
        "Odor identification and discrimination as markers of early Alzheimer\u2019s disease",
        "novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer\u2019s disease",
        "Olfactory dysfunction predicts 5-year mortality in older adults",
        "Olfactory dysfunction predicts subsequent dementia in older US adults",
        "Early detection of Parkinson\u2019s disease using deep learning and machine learning",
        "Early detection of Parkinson\u2019s disease by neural network models"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Second Century Fund",
        "Chulalongkorn University"
    ]
}